Skip to main content
SpringerLink
Log in

Misoprostol/NSAID Fixed Combinations

Help or Hindrance in Clinical Practice?

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pullar T, Wright V, Feeley M. What do patients and rheumatologists regard as an acceptable risk in the treatment of rheumatic diseases? Br J Rheumatol 1990; 29: 215–8

    Article  PubMed  CAS  Google Scholar 

  2. Committee on Safety of Medicines Update. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions — 1. BMJ 1986; 292: 614

    Article  Google Scholar 

  3. Agrawal N. Risk factors for gastrointestinal ulcers caused by nonsteroidal anti-inflammatory drugs. J Fam Pract 1991; 32: 619–24

    PubMed  CAS  Google Scholar 

  4. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet 1994; 343: 1075–8

    Article  PubMed  CAS  Google Scholar 

  5. Jones AC, Berman P, Doherty M. Nonsteroidal anti-inflammatory drug usage and requirement in elderly acute hospital admissions. Br J Rheumatol 1992; 31: 45–8

    Article  PubMed  CAS  Google Scholar 

  6. Brandt KD. Should nonsteroidal anti-inflammatory drugs be used to treat osteoarthritis? Rheum Dis Clin North Am 1993; 19(1): 29–44

    PubMed  CAS  Google Scholar 

  7. Helliwell PS. Treatment for non-inflammatory arthritis. Lancet 1994; 343: 1436

    Article  PubMed  CAS  Google Scholar 

  8. Hudson N, Faulkner G, Smith SJ, et al. Long term morbidity and management of patients surviving upper gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs. Gut 1992 Sep; Suppl. 33: S39 T155

  9. Grennan D, Aarons L, Siddiqui M, et al. Dose response study with ibuprofen in rheumatoid arthritis: clinical and pharmacokinetic findings. Br J Clin Pharmacol 1983; 15: 311–6

    Article  PubMed  CAS  Google Scholar 

  10. Seideman P, Melander A. Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis. Br J Rheumatol 1988; 27: 117–22

    Article  PubMed  CAS  Google Scholar 

  11. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232–5

    PubMed  CAS  Google Scholar 

  12. Abramson SB, Weissmann G. The mechanism of action of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1989; 32: 1–9

    Article  PubMed  CAS  Google Scholar 

  13. Appleton I, Tomlinson A, Willoughby DA. Inducible cyclo-oxygenase (COX-2): a safer therapeutic target? Br J Rheumatol 1994; 33: 410–2

    Article  PubMed  CAS  Google Scholar 

  14. Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol 1993; 88: 1318–23

    PubMed  CAS  Google Scholar 

  15. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078–88

    PubMed  CAS  Google Scholar 

  16. Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy. Arch Intern Med 1987; 147: 2093–100

    Article  PubMed  CAS  Google Scholar 

  17. Armstrong CP, Blower AL. Nonsteroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527–32

    Article  PubMed  CAS  Google Scholar 

  18. Jick SS, Walker AM, Perera DR, et al. Nonsteroidal anti-inflammatory drugs and hospital admission for perforated peptic ulcer. Lancet 1987; 2: 380–2

    Article  PubMed  CAS  Google Scholar 

  19. Caruso I, Porro GB. Gastroscopic evaluation of antiinflammatory agents. BMJ 1980; 1: 75–8

    Article  Google Scholar 

  20. Jaszewski R. Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or nonsteroidal anti-inflammatory drug therapy. J Clin Gastroenterol 1990; 12: 10–3

    Article  PubMed  CAS  Google Scholar 

  21. Geis GS, Stead H, Wallemark CB, et al. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol 1991; 18 Suppl. 28: 1277–80

    Google Scholar 

  22. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257–63

    PubMed  CAS  Google Scholar 

  23. Laporte J, Carne X, Vidal X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet 1991; 337: 85–9

    Article  PubMed  CAS  Google Scholar 

  24. Fries JF, Williams CA, Block DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91: 213–22

    Article  PubMed  CAS  Google Scholar 

  25. Nobunaga M. NSAID-induced GI damage: a serious problem? In: Nasution AR, Darmawam J, Isbagio H, editors. APLAR rheumatology 1992. Proceedings of the Seventh APLAR Congress of Rheumatology; 1992 Sept 13–18; Bali, Indonesia. New York: Churchill Livingstone, 1992: 319–22

    Google Scholar 

  26. Savage RL, Moller PW, Ballantyne CL, et al. Variation in the risk of peptic ulcer complications with nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1993; 36: 84–90

    Article  PubMed  CAS  Google Scholar 

  27. Beardon PHG, Brown SV, McDevitt DG. Gastrointestinal events in patients prescribed non-steroidal anti-inflammatory drugs: a controlled study using record linkage in Tayside. Q J Med 1989; 71: 497–505

    PubMed  CAS  Google Scholar 

  28. Janssen M, Dijkmans BAC, Lamers CBHW, et al. A gastroscopic study of the predictive value of risk factors for nonsteroidal anti-inflammatory drug-associated ulcer disease in rheumatoid arthritis patients. Br J Rheumatol 1994; 33: 449–54

    Article  PubMed  CAS  Google Scholar 

  29. Rodriguez LAG, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769–72

    Article  Google Scholar 

  30. Gabriel SE. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ameta-analysis. Ann Intern Med 1991; 115: 787–96

    PubMed  CAS  Google Scholar 

  31. Smith CC, Bennett PM, Pearce HM, et al. NSAIDs and gut toxicity. Lancet 1994; 344: 56–7

    Article  PubMed  CAS  Google Scholar 

  32. Levi S, Shaw-Smith C. Nonsteroidal anti-inflammatory drugs: how do they damage the gut? Br J Rheumatol 1994; 33: 605–12

    Article  PubMed  CAS  Google Scholar 

  33. Hayllar J, Smith T, Macpherson A, et al. Nonsteroidal anti-inflammatory drug-induced small intestinal inflammation and blood loss. Arthritis Rheum 1994; 37: 1146–50

    Article  PubMed  CAS  Google Scholar 

  34. Hawkey CJ. Nonsteroidal anti-inflammatory drugs and peptic ulcers. BMJ 1990; 300: 278–84

    Article  PubMed  CAS  Google Scholar 

  35. Semble EL, Wu WC. Antiinflammatory drugs and gastric mucosal damage. Semin Arthritis Rheum 1987; 16: 271–86

    Article  PubMed  CAS  Google Scholar 

  36. Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal use. Am J Gastroenterol 1987; 82: 1153–8

    PubMed  CAS  Google Scholar 

  37. Graham DY, Smith JL, Spjut HJ, et al. Gastric adaptation. Studies in humans during continuous aspirin administration. Gastroenterology 1988; 95: 327–33

    PubMed  CAS  Google Scholar 

  38. Hawthorne AB, Mahida YR, Cole AT, et al. Aspirin induced gastric mucosal damage: prevention by enteric coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991; 32: 77–83

    Article  PubMed  CAS  Google Scholar 

  39. Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979; 77: 761–7

    PubMed  CAS  Google Scholar 

  40. Barradell LB, Whittington R, Benfield P. Misoprostol. Pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs. Pharmacoeconomics 1993; 3(2): 140–70

    Article  PubMed  CAS  Google Scholar 

  41. Konturek SJ, Pawlik W. Physiology and pharmacology of prostaglandins. Dig Dis Sci 1986; 31(2): 6S-19S

    Article  Google Scholar 

  42. Levi S, Goodlad RA, Lee CY, et al. Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing. Lancet 1990; 2: 840–3

    Article  Google Scholar 

  43. Walen A, Bader JP, Meinhard C, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320: 69–75

    Article  Google Scholar 

  44. Roth SH, Agrawal NM, Mahawald M, et al. Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med 1989; 149: 775–9

    Article  PubMed  CAS  Google Scholar 

  45. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; 2: 1277–80

    Article  PubMed  CAS  Google Scholar 

  46. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119: 257–62

    PubMed  CAS  Google Scholar 

  47. Bardhan KD, Bjarnason I, Scott DL, et al. The prevention and healing of acute non-steroidal anti-inflammatory drug-associated gastroduodenal mucosal damage by misoprostol. Br J Rheumatol 1993; 32: 990–5

    Article  PubMed  CAS  Google Scholar 

  48. Bjarnason I, Smethhurst I, Fenn CG, et al. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989; 34: 407–11

    Article  PubMed  CAS  Google Scholar 

  49. Morris AJ, Murray L, Sturrock RD, et al. Short report: the effect of misoprostol on the anaemia of NSAID enteropathy. Aliment Pharmacol Ther 1994; 8: 343–6

    Article  PubMed  CAS  Google Scholar 

  50. Silverstein FE, Geis GS, Struthers BJ, et al. NSAIDs and gastrointestinal injury: clinical outcome, the MUCOSA trial. Gastroenterology 1994; 106: A180

    Google Scholar 

  51. Downie WW. Diclofenac/misoprostol: a review of the major clinical trials evaluating its clinical efficacy and upper gastrointestinal tolerability in rheumatoid arthritis and osteoarthritis. Drugs 1993; 45 Suppl. 1: 1–6

    Article  PubMed  Google Scholar 

  52. Gagnier P. Review of the safety of diclofenac/misoprostol. Drugs 1993; 45 Suppl. 1: 31–5

    Article  PubMed  Google Scholar 

  53. Melo Gomes JA, Roth SH, Zeeh J, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993; 52: 881–5

    Article  PubMed  CAS  Google Scholar 

  54. Wright V. Arthrotec: a review of a new concept in NSAID therapy. J Orthop Rheumatol 1993; 6: 129–33

    Google Scholar 

  55. Dammann HG, Simon-Schultz J, Steinhoff I, et al. Differential effects of misoprostol and ranitidine on the pharmacokinetics of diclofenac and gastrointestinal symptoms. Br J Clin Pharmacol 1993; 36: 345–9

    Article  PubMed  CAS  Google Scholar 

  56. Doube A, Davies J, Notarianni L, et al. Effect of misoprostol on concentrations of prostaglandins in synovial fluid. Ann Rheum Dis 1991; 50: 797–9

    Article  PubMed  CAS  Google Scholar 

  57. Shields MJ. Anti-inflammatory drugs and their effects on cartilage synthesis and renal function. Eur J Rheumatol Inflamm 1993; 13: 7–16

    Google Scholar 

  58. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989; 149: 2061–5

    Article  PubMed  CAS  Google Scholar 

  59. Carrin GJ, Torfs KE. Economic evaluation of prophylactic treatment with misoprostol in osteoarthritis patients treated with NSAIDs: the case of Belgium. Rev Epidemiol Sante Publique 1990; 38: 187–99

    PubMed  CAS  Google Scholar 

  60. Knill-Jones R, Drummond M, Kohli H, et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving nonsteroidal anti-inflammatory drugs. Postgrad Med J 1990; 66: 639–46

    Article  PubMed  CAS  Google Scholar 

  61. Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA 1990; 264: 41–7

    Article  PubMed  CAS  Google Scholar 

  62. de Pouvourville G. The economic consequences of NSAID-induced gastrointestinal damage. Eur J Rheumatol Inflamm 1993; 13: 33–40

    PubMed  Google Scholar 

  63. Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal anti-inflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993; 36: 447–59

    Article  PubMed  CAS  Google Scholar 

  64. Gabriel SE, Campion ME, O’Fallon WM. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994; 37: 333–41

    Article  PubMed  CAS  Google Scholar 

  65. Gabriel SE. Is misoprostol prophylaxis indicated for NSAID induced adverse gastrointestinal events? An epidemiologic opinion. J Rheumatol 1991; 18(7): 958–9

    PubMed  CAS  Google Scholar 

  66. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. Number 29. London: British Medical Association, March 1995

    Google Scholar 

  67. Hawkey C. Non-steroidal anti-inflammatory drugs in patients with peptic ulcer disease: rarely justified in terms of cost or patient benefit. BMJ 1989; 298: 177–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatology and Rehabilitation Research Unit, Research School of Medicine, University of Leeds, 36 Clarendon Road, Leeds, LS2 9NZ, UK

    Amanda Isdale & Verna Wright

Authors
  1. Amanda Isdale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Verna Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Isdale, A., Wright, V. Misoprostol/NSAID Fixed Combinations. Drug-Safety 12, 291–298 (1995). https://doi.org/10.2165/00002018-199512050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199512050-00001

Keywords

Search

Navigation